<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04890509</url>
  </required_header>
  <id_info>
    <org_study_id>BGBC020</org_study_id>
    <nct_id>NCT04890509</nct_id>
  </id_info>
  <brief_title>A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients</brief_title>
  <official_title>A Multicentre, Phase 2, Randomised Study to Assess the Efficacy and Safety of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BerGenBio ASA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BerGenBio ASA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the efficacy of bemcentinib as an add-on&#xD;
      therapies to standard of care (SoC) in participants hospitalized with coronavirus disease&#xD;
      2019 (COVID-19).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Actual">May 25, 2021</completion_date>
  <primary_completion_date type="Actual">May 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Sustained Clinical Improvement of at Least 2 Points (from randomization)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Sustained clinical improvement is defined as improvement without subsequent worsening. Time to sustained clinical improvement of at least 2 points (from randomization) on a 9-point category ordinal scale. Live discharge from the hospital, or considered fit for discharge whichever comes first, by Day 29 will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants not Deteriorating According to the Ordinal Scale by 1, 2, or 3 Points</measure>
    <time_frame>At Days 2, 8, 15, and 29</time_frame>
    <description>Percentage of participants not deteriorating according to the 9-point category Ordinal Scale (0= uninfected and 8= Death), by 1, 2, or 3 Points will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Oxygen Use</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Duration of oxygen use in terms of days will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Oxygen-free Days</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Number of oxygen-free days will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load</measure>
    <time_frame>At Days 1, 3, 5, 8, 11, 15, and 29</time_frame>
    <description>SARS-CoV-2 viral load will be determined by polymerase chain reaction (PCR) in oropharyngeal/nasal swab while hospitalized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Ventilation</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Duration of ventilation will be reported in terms of days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Ventilation-free Days</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Number of ventilation-free days will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Any Form of New Ventilation Use</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Number of participants with any form of new ventilation use will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of New Ventilation Use</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Duration of new ventilation use will be reported in terms of days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Organ Support</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Duration of organ support (e.g., including respiratory, renal, and cardiac support) will be calculated in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Response</measure>
    <time_frame>At Days 2, 8, 15, and 29</time_frame>
    <description>Response Rate will be assessed on a 9-point category ordinal scale. Number of participants with response (defined as sustained clinical improvement of at least 2 points (from randomization) on a 9-point category ordinal scale, live discharge from the hospital, or considered fit for discharge (a score of 0, 1, or 2 on the ordinal scale), whichever comes first) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Live Discharge From the Hospital</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Time to live discharge from the hospital will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Treatment Start Date to Death</measure>
    <time_frame>Up to Day 60</time_frame>
    <description>Time from treatment start date to death will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mortality</measure>
    <time_frame>At Days 15, 29, and 60</time_frame>
    <description>Number of deaths will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Ratio of Oxygen Saturation to Fraction of Inspired Oxygen Concentration (SpO2/FiO2)</measure>
    <time_frame>From randomization to Day 15, hospital discharge, or death (Up to 90 days)</time_frame>
    <description>Change in the ratio of the oxygen saturation to fraction of inspired oxygen concentration (SpO2/FiO2) will be measured daily from randomization to Day 15, hospital discharge, or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Physical Examination Abnormalities</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of participants with physical examinations (including presenting signs, height, weight) abnormalities will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinical Laboratory Abnormalities</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Number of participants with clinical laboratory (Haematology, chemistry, liver function tests, coagulation) abnormalities will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Vital Signs (blood pressure/heart rate/temperature/respiratory rate) Abnormalities</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Number of participants with vital signs (blood pressure/heart rate/temperature/respiratory rate) abnormalities will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>From Baseline to Day 90</time_frame>
    <description>An AE is any untoward medical occurrence in participants, temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Intensive Care Unit (ICU) and Hospitalization</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Duration of ICU and hospitalization will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Early Warning Score 2 (NEWS2)</measure>
    <time_frame>At Days 15 and 29</time_frame>
    <description>The NEWS2 is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice presentation or when a patient is being monitored in hospital. The score ranges from 0 (best) to 23 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to NEWS2 of &lt;=2, Maintained for at Least 24 Hours</measure>
    <time_frame>At Days 15 and 29</time_frame>
    <description>The NEWS2 is based on a simple aggregate scoring system in which a score is allocated to physiological measurements. The score ranges from 0 (best) to 23 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ranked Trajectory</measure>
    <time_frame>29 days</time_frame>
    <description>Ranked trajectory will be calculated over 29 days, with trajectory ranked of the ordinal scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Standard of Care + Bemcentinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bemcentinib will be administered for up to 15 days, or until discharge from hospital, whichever comes sooner. SoC will be administered based on local guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The SoC will be administered based on local guidelines in place at the time of treatment during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bemcentinib</intervention_name>
    <description>Bemcentinib capsules will be administered orally.</description>
    <arm_group_label>Standard of Care + Bemcentinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SoC</intervention_name>
    <description>The SoC will be administered based on local guidelines.</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_label>Standard of Care + Bemcentinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (greater than or equal to [&gt;=] 18 years) with SARS-CoV-2 infection.&#xD;
&#xD;
          -  Participants with symptoms and/or signs consistent with COVID-19, requiring treatment.&#xD;
&#xD;
          -  A score of Grade 3 to 5 on the 9-point ordinal scale. In India; only Participants with&#xD;
             a score of Grade 4 or 5 will be enrolled.&#xD;
&#xD;
          -  a) Male Participants:&#xD;
&#xD;
          -  A male Participant must agree to use contraception during the treatment period and for&#xD;
             at least 120 days after the last dose of study treatment and refrain from donating&#xD;
             sperm during this period.&#xD;
&#xD;
             b) Female Participants:&#xD;
&#xD;
          -  A female Participant is eligible to participate if she is not pregnant, not&#xD;
             breastfeeding, and at least 1 of the following conditions applies:&#xD;
&#xD;
               1. Not a woman of childbearing potential. OR&#xD;
&#xD;
               2. A woman of childbearing potential who agrees to follow the contraceptive guidance&#xD;
                  during the treatment period and for at least 120 days after the last dose of&#xD;
                  study treatment.&#xD;
&#xD;
          -  Women who are lactating who agree not to breastfeed their child during the study and&#xD;
             for at least 120 days after termination of study therapy (they may continue to express&#xD;
             milk away from the child during this period, but this milk must be discarded).&#xD;
&#xD;
          -  Ability to provide informed consent signed by the study Participant or legally&#xD;
             authorized representative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who have previously had a score of 6 or 7 on the 9-point ordinal scale.&#xD;
&#xD;
          -  Inability to swallow capsules (administration via nasogastric tube is permitted in&#xD;
             Participants who become unable to swallow after starting the study drug).&#xD;
&#xD;
          -  History of the following cardiac conditions:&#xD;
&#xD;
               1. Myocardial infarction within 3 months prior to the first dose&#xD;
&#xD;
               2. Unstable angina&#xD;
&#xD;
               3. History of clinically significant dysrhythmias (long QT features on&#xD;
                  electrocardiogram [ECG], sustained bradycardia [less than or equal to {&lt;=} 55&#xD;
                  beats per minute {bpm}]), left bundle branch block, or ventricular arrhythmia) or&#xD;
                  history of familial long QT. Participants with an implantable cardioverter&#xD;
                  defibrillator device in place, will be allowed to enroll. Atrial fibrillation&#xD;
                  will not be a reason for exclusion.&#xD;
&#xD;
          -  Screening 12-lead ECG with a measurable QT interval according to Fridericia correction&#xD;
             (QTcF) greater than (&gt;) 470 msec.&#xD;
&#xD;
          -  Clinically significant hypokalaemia.&#xD;
&#xD;
          -  Therapeutic anticoagulation with vitamin K antagonists.&#xD;
&#xD;
          -  Previous bowel resection that would interfere with drug absorption.&#xD;
&#xD;
          -  Any participant whose interests are not best served by study participation, as&#xD;
             determined by a senior attending clinician.&#xD;
&#xD;
          -  Alanine aminotransferase/aspartate aminotransferase &gt;5 Ã— the upper limit of normal.&#xD;
&#xD;
          -  Current treatment for human immunodeficiency virus (HIV) or tuberculosis (TB).&#xD;
&#xD;
          -  Positive serologic assay at screening for hepatitis B virus (Hep B surface antigen) or&#xD;
             hepatitis C virus (hepatitis C PCR or hepatitis C core antigen) at local laboratory.&#xD;
&#xD;
          -  Stage 4 severe chronic kidney disease.&#xD;
&#xD;
          -  Anticipated transfer to another hospital that is not a study center within 72 hours.&#xD;
&#xD;
          -  Allergy to any study treatment.&#xD;
&#xD;
          -  Experimental off-label usage of medicinal products as treatments for COVID-19 at the&#xD;
             time of enrolment.&#xD;
&#xD;
          -  Participants participating in another clinical study of an investigational medicinal&#xD;
             product.&#xD;
&#xD;
          -  Current or planned treatment for TB.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hani Gabra</last_name>
    <role>Study Chair</role>
    <affiliation>BerGenBio ASA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nirmal Hospital Private Limited</name>
      <address>
        <city>Surat</city>
        <state>Gujarat</state>
        <zip>395002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasturba Medical College</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>575001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSS Hospital</name>
      <address>
        <city>Mysuru</city>
        <state>Karnataka</state>
        <zip>570 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chopda Medicare &amp; Research Centre Pvt. Ltd (CMARC) - Magnum Heart Institute</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahyadri Specialty Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharastra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krishna Institute of Medical Sciences (KIMS Hospitals)</name>
      <address>
        <city>Secunderabad</city>
        <state>Telangana</state>
        <zip>500003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maulana Azad Medical College</name>
      <address>
        <city>New Delhi</city>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worthwhile Clinical Trials, Lakeview Hospital</name>
      <address>
        <city>Mowbray</city>
        <state>Benoni</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tiervlei Trial Centre</name>
      <address>
        <city>Bellville</city>
        <state>Cape Town</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vergelegen Mediclinic</name>
      <address>
        <city>Somerset West</city>
        <state>Cape Town</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Into Research</name>
      <address>
        <city>Groenkloof</city>
        <state>Pretoria</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Projects Research</name>
      <address>
        <city>Worcester</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in the article, after deidentification [text, tables, figures and appendices].</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication</ipd_time_frame>
    <ipd_access_criteria>Proposal should be directed to HYPERLINK &quot;mailto:clinical@bergenbio.com&quot; clinical@bergenbio.com. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

